Radient Pharmaceuticals Onko-Sure(R) In Vitro Diagnostic Cancer Test Potentially Effective as Veterinary Cancer Tumor Marker
December 08 2010 - 7:45AM
Marketwired
Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) today
announced it has completed a pilot clinical study to measure the
feasibility of using its Onko-Sure® in vitro diagnostic (IVD)
cancer test kit as a veterinary tumor marker initially for cancer
detection in domestic cats.
Preliminary data from the Onko-Sure® assay pilot study measuring
domestic cat serum suggests RPC's Onko-Sure® IVD cancer test may
potentially detect cancer in domestic cats. In this pilot study,
RPC ran samples from confirmed normal domestic cats and domestic
cats with cancer. For cats with cancer, RPC ran a serum sample
obtained first when the cats were cancer-free and another sample
subsequently when the cats were confirmed with cancer. The relative
levels of Onko-Sure® for the cats were compared using the Onko-Sure
assay and showed a 2,853% increase in Onko-Sure levels versus the
healthy sample. RPC is currently engaged in full clinical trial
including 71 samples, which includes an antigen characterization
that involves testing to identify direct evidence that RPC's
Onko-Sure® IVD cancer test kits are effective in cancer detection
in domestic felines.
According to Douglas MacLellan, Chairman and CEO of Radient
Pharmaceuticals, "This development is anticipated to open the use
of our Onko-Sure® assay as a veterinary cancer tool that could play
an integral role in the screening and early detection of cancer for
veterinary patients and further enhance RPC's strong portfolio of
novel oncology products. This is truly an exciting development for
the Company and our valued shareholders."
Onko-Sure is a simple, non-invasive, patent-pending and
regulatory-approved IVD test for use as an aid in early detection
of cancer. Onko-Sure enables physicians and their patients to
effectively monitor and/or detect certain types of cancers by
measuring the accumulation of specific breakdown products in the
blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP
levels rise dramatically with the progression of cancer. Onko-Sure
is approved by the US FDA for the monitoring of colorectal cancer,
Health Canada as a lung cancer screen and cancer monitoring tool,
and the European Union, Indian government, Korean government, and
Taiwanese government as a cancer monitoring or cancer screening
test. Onko-Sure test kits are currently sold as a blood test for
cancer in Europe, India, Taiwan, Korea, and Vietnam and in Chili
for research use.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is
dedicated to saving lives and money for patients and global
healthcare systems through the deployment of its FDA-cleared In
Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer
recurrence monitoring The company's focus is on the discovery,
development and commercialization of unique high-value diagnostic
tests that help physicians answer important clinical questions
related to early disease-state detection, treatment strategy and
the monitoring of disease progression or recurrence. To learn more
about our company, people and potentially life-saving cancer test,
visit.
Forward-Looking Statements: Safe Harbor
Statement under the Private Securities Litigation Reform Act of
1995: The statements contained in this document include certain
predictions and projections that may be considered forward-looking
statements under securities law. These statements involve a number
of important risks and uncertainties that could cause actual
results to differ materially including, but not limited to, the
performance of joint venture partners, as well as other economic,
competitive and technological factors involving the Company's
operations, markets, services, products, and prices. With respect
to Radient Pharmaceuticals Corporation, except for the historical
information contained herein, the matters discussed in this
document are forward-looking statements involving risks and
uncertainties that could cause actual results to differ materially
from those in such forward-looking statements.
Add to Digg Bookmark with del.icio.us Add to Newsvine
RPC Contact: Kristine Szarkowitz Director-Investor Relations
Email Contact Tel: 206.310.5323